COMMUNIQUÉS West-GlobeNewswire

Radient Technologies Inc. Announces Master Services Agreement with Medical Cannabis Supplier Bonify

26/02/2018 - 14:00

EDMONTON, Alberta, Feb. 26, 2018 (GLOBE NEWSWIRE) -- Radient Technologies Inc . ("Radient" or the “Company”) (TSX-V: RTI ) announces the signing of a Master Services Agreement (the “Agreement”) to produce a variety of [...]

Extendicare Announces Agreement to Acquire Lynde Creek Retirement Community

26/02/2018 - 14:00

MARKHAM, Ontario, Feb. 26, 2018 (GLOBE NEWSWIRE) -- Extendicare Inc. (“Extendicare” or the “Company”) (TSX: EXE ) today announced that it has entered into a definitive agreement to acquire the Lynde Creek Retirement [...]

Endocyte and ITM Announce Supply Agreement for No-Carrier-Added Lutetium for the Phase 3 VISION Trial

26/02/2018 - 14:00

WEST LAFAYETTE, Ind. and MUNICH, Germany, Feb. 26, 2018 (GLOBE NEWSWIRE) -- Endocyte, Inc. (NASDAQ: ECYT ), and ITM Isotopen Technologien München AG (ITM), a specialized radiopharmaceutical company, today announced a [...]

Hemostemix Signs License Agreement with Aspire Health Science

26/02/2018 - 14:00

CALGARY, Alberta, Feb. 26, 2018 (GLOBE NEWSWIRE) -- Hemostemix Inc . (“ Hemostemix ” or the “ Company ”) (TSX VENTURE:HEM) is pleased to announce it has finalized the terms of a license agreement (the “ License [...]

PotNetwork Holding’s Diamond CBD Books Over $270,000 in Sales at CHAMPS Winter Show at Las Vegas Convention Center

26/02/2018 - 13:37

FT. LAUDERDALE, Fla., Feb. 26, 2018 (GLOBE NEWSWIRE) -- Via OTC PR Wire -- PotNetwork Holding Inc. (OTC Pink:POTN ) is pleased to announce that its wholly owned subsidiary, Diamond CBD , Inc., which exhibited its 2018 [...]

Avadel Pharmaceuticals to Report Fourth Quarter and Full Year 2017 Results

26/02/2018 - 13:30

DUBLIN, Ireland, Feb. 26, 2018 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (NASDAQ: AVDL ), today announced it will report its fourth quarter and full year 2017 financial results on Thursday, March 8, 2018, before [...]

Strongbridge Biopharma plc Announces Underwriters’ Partial Exercise of Option to Purchase Additional Shares

26/02/2018 - 13:30

DUBLIN, Ireland and TREVOSE, Penn. , Feb. 26, 2018 (GLOBE NEWSWIRE) -- Strongbridge Biopharma plc (NASDAQ: SBBP ) (the “Company”) today announced that the underwriters of its previously announced underwritten public [...]

SAVE THE DATE: Ninth Annual "Mardi Gras for Autism" Expects 4,000 Attendees at Fullerton Cares Event Raising Awareness for Autism – 4/7/2018

26/02/2018 - 13:30

FULLERTON, Calif., Feb. 26, 2018 (GLOBE NEWSWIRE) -- To support autism charities and special education, Fullerton Cares’ ninth annual FREE family carnival benefit, “Mardi Gras for Autism” will be held outside Bourbon [...]

The Joint Corp. to Present at the 30th Annual ROTH Conference

26/02/2018 - 13:05

SCOTTSDALE, Ariz., Feb. 26, 2018 (GLOBE NEWSWIRE) -- The Joint Corp. (NASDAQ: JYNT ), a national operator, manager and franchisor of chiropractic clinics, announced it will present at the 30 th Annual ROTH Conference on [...]

ObsEva SA Reports Positive Topline Results from IMPLANT2 Phase 3 Clinical Trial of Nolasiban in IVF

26/02/2018 - 13:01

The WHO considers infertility a global public health issue affecting 186 million people, and only 1 in 4 ART treatments results in childbirth Geneva, Switzerland and Boston, MA - 26 February, 2018 - ObsEva SA (NASDAQ: [...]

Summit Therapeutics plc : Research Update

26/02/2018 - 13:01

Summit Therapeutics plc ('Summit', or 'the Company') SUMMIT ANNOUNCES NEW ANALYSIS SHOWING EZUTROMID SIGNIFICANTLY REDUCED MUSCLE INFLAMMATION IN PHASE 2 CLINICAL TRIAL IN DMD MRS-T2 Data Provide Evidence of Early [...]

Summit Announces New Analysis Showing Ezutromid Significantly Reduced Muscle Inflammation in Phase 2 Clinical Trial in DMD

26/02/2018 - 13:00

MRS-T2 Data Provide Evidence of Early Impact of Ezutromid on Downstream Muscle Health Data Build on Positive Biopsy Findings that Showed Significant Decrease in Muscle Damage OXFORD, United Kingdom, Feb. 26, 2018 (GLOBE [...]

Cesca Therapeutics Inc. Announces Commercial Launch of AXP® II System for Advanced Cord Blood Processing

26/02/2018 - 13:00

RANCHO CORDOVA, Calif., Feb. 26, 2018 (GLOBE NEWSWIRE) -- Cesca Therapeutics Inc. (“Cesca”) (NASDAQ: KOOL ) a market leader in automated cell processing and point-of-care, autologous cell-based therapies, today [...]

Protalix BioTherapeutics to Hold Full-Year 2017 Financial Results and Corporate Update Conference Call on March 6, 2018

26/02/2018 - 13:00

CARMIEL, Israel, Feb. 26, 2018 (GLOBE NEWSWIRE) -- Protalix BioTherapeutics, Inc. (NYSE American:PLX) (TASE: PLX ), a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic [...]

Axsome Therapeutics Announces Primary Endpoint Met in Phase 1 Trial of Next Generation Product Candidate AXS-09 Containing Chirally Pure Esbupropion and Dextromethorphan

26/02/2018 - 13:00

Chirally pure and stable single enantiomers of bupropion achieved AXS-09 consists of esbupropion and dextromethorphan for CNS disorders Esbupropion is the chirally pure S -enantiomer of bupropion AXS-09 results in [...]

Edge Therapeutics Announces Fourth Quarter and Full Year 2017 Financial Results Conference Call on March 1, 2018

26/02/2018 - 13:00

BERKELEY HEIGHTS, N.J., Feb. 26, 2018 (GLOBE NEWSWIRE) -- Edge Therapeutics, Inc. (Nasdaq: EDGE ), a clinical-stage biotechnology company developing novel hospital-based therapies in the management of acute, life- [...]

Resverlogix Announces Sixth Positive Recommendation From Data Safety Monitoring Board For Phase 3 Study of Apabetalone

26/02/2018 - 13:00

CALGARY, Alberta, Feb. 26, 2018 (GLOBE NEWSWIRE) -- Resverlogix Corp. (“Resverlogix” or the "Company") (TSX: RVX ) today announced that the independent Data and Safety Monitoring Board (DSMB) for the Company's Phase 3 [...]

Achillion Announces ACH-4471 Receives Positive Opinion for Orphan Drug Designation in the European Union for the Treatment of C3 Glomerulopathy

26/02/2018 - 12:05

NEW HAVEN, Conn., Feb. 26, 2018 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq: ACHN ), a biopharmaceutical company focused on advancing small molecule factor D inhibitors to modulate the complement [...]

Orion Group Financial Statement documents 2017 and Corporate Governance Statement published

26/02/2018 - 12:02

ORION CORPORATION STOCK EXCHANGE RELEASE 26 FEBRUARY 2018 at 13.00 EET Orion Group Financial Statement documents 2017 and Corporate Governance Statement published Orion Group's Financial Statement documents for 2017 [...]